logo-loader
viewInnoCan Pharma

Innocan Pharma amends unit price of $10M offering

The company plans to use the proceeds for research and product development expenses, marketing expenses, and administrative expenses

Toy person shoveling money
Innocan Pharma is a specialty pharma company, which develops products that harness the properties of cannabinoids combined with smart delivery formulations

InnoCan Pharma Corporation (CSE:INNO) announced Tuesday that it amended terms to its previously announced potential C$10 million offering, through which the company expects to fund research and development, marketing and operations expenses.

The company will offer units, each containing one common share and one purchase warrant, at a new price of C$0.18 per unit, shifted from C$0.20. The move is expected to fetch gross proceeds of at least C$2.5 million and up to C$10 million.

The warrants are exercisable at a price of C$0.25 per share for a period of 36 months, the company said. Innocan can accelerate that date with written notice if its stock trades above C$0.50 per share for 20 consecutive trading days.

READ: InnoCan Pharma files patent application for novel cannabis-based treatment for skin disorder psoriasis

Innocan Pharma is a specialty pharma, which develops products that harness the properties of cannabinoids combined with smart delivery formulations.

The offer is being led by Mackie Research Capital, as sole bookrunner, and Canaccord Genuity as co-lead agents, together with Haywood Securities Inc and PI Financial Corp.

InnoCan has also granted its agents an option to cover over-allotments and for market stabilization purposes, exercisable in whole or in part at any time up to 30 days from the closing, to increase the size of the offering by up to 15% of the number of units sold.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: InnoCan Pharma

Price: 0.22 CAD

CSE:INNO
Market: CSE
Market Cap: $31.65 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of InnoCan Pharma named herein, including the promotion by the Company of InnoCan Pharma in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Innocan Pharma received U.S. FDA approval for their over the counter CBD...

Innocan Pharma (CSE: INNO) CEO Iris Bincovich joined Steve Darling from Proactive Vancouver with news the company has just received FDA approval in the United States for their patent-pending CBD Relief &GO pain relief collection. Bincovich talks about the collection and when they would...

2 weeks, 1 day ago

2 min read